| Year |
Citation |
Score |
| 2014 |
Sayyah J, Bartakova A, Nogal N, Quilliam LA, Stupack DG, Brown JH. The Ras-related protein, Rap1A, mediates thrombin-stimulated, integrin-dependent glioblastoma cell proliferation and tumor growth. The Journal of Biological Chemistry. 289: 17689-98. PMID 24790104 DOI: 10.1074/Jbc.M113.536227 |
0.479 |
|
| 2013 |
Sayyah J, Stupack D, Brown JH. Abstract 4101: Thrombin stimulates glioblastoma cell proliferation, adhesion and in vivo tumor growth through Rap1 activation. Cancer Research. 73: 4101-4101. DOI: 10.1158/1538-7445.Am2013-4101 |
0.461 |
|
| 2012 |
Ortiz-Sanchez JM, Nichols SE, Sayyah J, Brown JH, McCammon JA, Grant BJ. Identification of potential small molecule binding pockets on Rho family GTPases. Plos One. 7: e40809. PMID 22815826 DOI: 10.1371/Journal.Pone.0040809 |
0.375 |
|
| 2011 |
Sayyah J, Gnanasambandan K, Kamarajugadda S, Tsuda S, Caldwell-Busby J, Sayeski PP. Phosphorylation of Y372 is critical for Jak2 tyrosine kinase activation. Cellular Signalling. 23: 1806-15. PMID 21726629 DOI: 10.1016/J.Cellsig.2011.06.015 |
0.594 |
|
| 2009 |
Kiss R, Polgár T, Kirabo A, Sayyah J, Figueroa NC, List AF, Sokol L, Zuckerman KS, Gali M, Bisht KS, Sayeski PP, Keseru GM. Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorganic & Medicinal Chemistry Letters. 19: 3598-601. PMID 19447617 DOI: 10.1016/J.Bmcl.2009.04.138 |
0.73 |
|
| 2009 |
Sayyah J, Sayeski PP. Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies. Current Oncology Reports. 11: 117-24. PMID 19216843 DOI: 10.1007/S11912-009-0018-2 |
0.678 |
|
| 2008 |
Sayyah J, Magis A, Ostrov DA, Allan RW, Braylan RC, Sayeski PP. Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth. Molecular Cancer Therapeutics. 7: 2308-18. PMID 18723478 DOI: 10.1158/1535-7163.Mct-08-0279 |
0.748 |
|
| 2007 |
Godeny MD, Sayyah J, VonDerLinden D, Johns M, Ostrov DA, Caldwell-Busby J, Sayeski PP. The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT1 receptor. Cellular Signalling. 19: 600-9. PMID 17027227 DOI: 10.1016/J.Cellsig.2006.08.010 |
0.667 |
|
| 2007 |
Sayyah J, Allen RW, Braylan RC, Keseru GM, Sayeski PP. Identification and Characterization of a Series of Novel Jak2 Small Molecule Inhibitor Compounds. Blood. 110: 539-539. DOI: 10.1182/Blood.V110.11.539.539 |
0.672 |
|
| 2006 |
Sayyah J, Ostrov D, Sayeski P. Identification and Characterization of a Novel Jak2 Tyrosine Kinase Inhibitor. Blood. 108: 3604-3604. DOI: 10.1182/Blood.V108.11.3604.3604 |
0.768 |
|
| 2005 |
Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Research. 65: 8423-32. PMID 16166321 DOI: 10.1158/0008-5472.Can-05-0058 |
0.53 |
|
| 2005 |
Tsurutani J, Castillo SS, Brognard J, Granville CA, Zhang C, Gills JJ, Sayyah J, Dennis PA. Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis. 26: 1182-95. PMID 15790591 DOI: 10.1093/Carcin/Bgi072 |
0.334 |
|
| Show low-probability matches. |